Literature DB >> 925011

Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling.

R H Zaugg, J A Walder, I M Klotz.   

Abstract

Normal and sickle erythrocytes were exposed in vitro to millimolar concentrations of 31 different carbonyl compounds. Schiff base (imine) linkages were formed with amino groups of intracellular hemoglobin. Adducts were isolated by gel electrofocusing and could be dissociated by dialysis. Aromatic aldehydes proved more reactive than aliphatic aldehydes, and ketones were unreactive. The influence of various ring substituents on the reactivity of aromatic aldehydes was found to conform closely to traditional concepts regarding electronic and steric effects. Several of the aromatic aldehydes were shown to markedly increase the oxygen affinity of hemoglobins A and S. In particular, 2,4-dihydroxybenzaldehyde and o-vanillin, at concentrations of 5 mM, produced 2- to 3-fold reductions in the P50 (partial pressure of oxygen at half-saturation) of sickle hemoglobin in whole blood. Since low degrees of oxygen saturation promote erythrocyte sickling, compounds of this type significantly inhibit sickling at reduced partial pressures of oxygen.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 925011

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers.

Authors:  Anton B Iliuk; Victoria A Martin; Bethany M Alicie; Robert L Geahlen; W Andy Tao
Journal:  Mol Cell Proteomics       Date:  2010-06-17       Impact factor: 5.911

2.  Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.

Authors:  Piyusha P Pagare; Mohini S Ghatge; Faik N Musayev; Tanvi M Deshpande; Qiukan Chen; Courtney Braxton; Solyi Kim; Jürgen Venitz; Yan Zhang; Osheiza Abdulmalik; Martin K Safo
Journal:  Bioorg Med Chem       Date:  2018-04-06       Impact factor: 3.641

3.  Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.

Authors:  A M Omar; M A Mahran; M S Ghatge; N Chowdhury; F H A Bamane; M E El-Araby; O Abdulmalik; M K Safo
Journal:  Org Biomol Chem       Date:  2015-06-14       Impact factor: 3.876

4.  The anti-sickling activity of a series of aromatic aldehydes [proceedings].

Authors:  C R Beddell; G Kneen; R D White
Journal:  Br J Pharmacol       Date:  1979-05       Impact factor: 8.739

5.  Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin.

Authors:  Osheiza Abdulmalik; Mohini S Ghatge; Faik N Musayev; Apurvasena Parikh; Qiukan Chen; Jisheng Yang; Ijeoma Nnamani; Richmond Danso-Danquah; Dorothy N Eseonu; Toshio Asakura; Donald J Abraham; Jurgen Venitz; Martin K Safo
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-10-19

Review 6.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

Authors:  Martin K Safo; Gregory J Kato
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-21       Impact factor: 3.722

7.  Fixation of various aldehydic dextrans onto human hemoglobin: study of conjugate stability.

Authors:  F Bonneaux; E Dellacherie
Journal:  J Protein Chem       Date:  1995-01

8.  Pyridoxal phosphate as an antisickling agent in vitro.

Authors:  J A Kark; P G Tarassoff; R Bongiovanni
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

Review 9.  New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?

Authors:  Esther Oder; Martin K Safo; Osheiza Abdulmalik; Gregory J Kato
Journal:  Br J Haematol       Date:  2016-09-08       Impact factor: 6.998

10.  Characterization of the binding of the anti-sickling compound, BW12C, to haemoglobin.

Authors:  M Merrett; D K Stammers; R D White; R Wootton; G Kneen
Journal:  Biochem J       Date:  1986-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.